Mineralys Therapeutics (MLYS) Other financing activities (2023 - 2026)
Mineralys Therapeutics (MLYS) reported Other financing activities of $4.1 million for Q1 2026, up 3196.75% on a YoY basis from $123000.0 in Q1 2025, and up 2955.63% sequentially from -$142000.0 in Q4 2025.
Mineralys Therapeutics (MLYS) Other financing activities (2023 - 2026) Analysis & Trends
Mineralys Therapeutics (MLYS) has 4 years of Other financing activities data on file, last reported at $4.1 million in Q1 2026.
- For the quarter ending Q1 2026, Other financing activities rose 3196.75% year-over-year to $4.1 million; the trailing twelve-month figure through Mar 2026 stood at $3.9 million (up 103.4% YoY), and the FY2024 full-year result was $221000.0, changed N/A from the prior year.
- Other financing activities rose to $4.1 million in Q1 2026, from -$142000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $203.0 million in Q3 2023 to a low of -$203.0 million in Q4 2023.
- A 4-year average of $388727.3 and a median of $83000.0 in 2024 frame the typical range for Other financing activities.
- Across the five-year window, Other financing activities plunged 271.08% in 2025 and jumped 3196.75% in 2026, its largest moves.
- Tracing MLYS's Other financing activities over 4 years: stood at -$203.0 million in 2023, then jumped by 100.04% to $83000.0 in 2024, then sank by 271.08% to -$142000.0 in 2025, then jumped by 2955.63% to $4.1 million in 2026.
- Business Quant data shows MLYS's Other financing activities at $4.1 million in Q1 2026, -$142000.0 in Q4 2025, and $142000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Mineralys Therapeutics | 2.24 Bn | 2.24 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.06 Mn |
| Mar 31, 2026 | 4.06 Mn |
| Dec 31, 2025 | -142,000.00 |
| Dec 31, 2025 | -142,000.00 |
| Sep 30, 2025 | 142,000.00 |
| Sep 30, 2025 | 142,000.00 |
| Jun 30, 2025 | -123,000.00 |
| Jun 30, 2025 | -123,000.00 |
| Mar 31, 2025 | 123,000.00 |
| Mar 31, 2025 | 123,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Sep 30, 2024 | -115.92 Mn |
| Sep 30, 2024 | -115.92 Mn |
| Jun 30, 2024 | -60,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Mar 31, 2024 | 116.12 Mn |
| Mar 31, 2024 | 116.12 Mn |
| Dec 31, 2023 | -202.99 Mn |
| Dec 31, 2023 | -202.99 Mn |